

Research

A mathematical model for the burden of diabetes and its complications

A Boutayeb^{*1,2}, EH Twizell¹, K Achouayb² and A Chetouani²

Address: ¹Department of mathematics and statistics, Brunel University, Uxbridge middx UB8 3PH, UK and ²Department of mathematics, Faculty of sciences, Oujda, Morocco

Email: A Boutayeb^{*} - masraab@brunel.ac.uk; EH Twizell - E.H.Twizell@brunel.ac.uk; K Achouayb - aassil@hotmail.com; A Chetouani - chetouani@sciences.univ-oujda.ac.ma

^{*} Corresponding author

Published: 28 June 2004

Received: 26 March 2004

BioMedical Engineering OnLine 2004, 3:20 doi:10.1186/1475-925X-3-20

Accepted: 28 June 2004

This article is available from: <http://www.biomedical-engineering-online.com/content/3/1/20>

© 2004 Boutayeb et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: The incidence and prevalence of diabetes are increasing all over the world. Complications of diabetes constitute a burden for the individuals and the whole society.

Methods: In the present paper, ordinary differential equations and numerical approximations are used to monitor the size of populations of diabetes with and without complications.

Results: Different scenarios are discussed according to a set of parameters and the dynamical evolution of the population from the stage of diabetes to the stage of diabetes with complications is clearly illustrated.

Conclusions: The model shows how efficient and cost-effective strategies can be obtained by acting on diabetes incidence and/or controlling the evolution to the stage of complications.

Background

It is now commonly admitted that diabetes is sweeping the globe as a silent epidemic largely contributing to the growing burden of non-communicable diseases and mainly encouraged by decreasing levels of activity and increasing prevalence of obesity. The recent reports released by the World Health Organization [1] and the International Diabetes Federation [2] are alarming. In 2003, it was estimated that 194 million people were diabetic, representing a global prevalence exceeding 3% (5.1% for those aged 20 to 79) of the world population. The trend is increasing and the number is expected to reach 333 million (6.3%) by the year 2025. Moreover, for the first time, an estimation of 314 million (8.2%) is given for people in the pre-diabetic stage which constitutes a compartment from which at least one third will evolve to the diabetic stage after 10 years.

Dramatic increase have occurred in both prevalence and incidence of diabetes globally, especially with the new threshold proposed by the Expert Committee on the diagnosis and classification of diabetes mellitus in 1997 [3] and adopted by the World Health Organization. But it is worth noting the growing part of developing countries as stressed by many authors [4-6] and summarized in Table 1 for the ten leading countries [2]. In general, two forms of diabetes are considered: Type 1 diabetes, also known as Insulin Dependent Diabetes Mellitus (IDDM), affecting people under the age of 40 and representing 10 to 15% of the diabetic population, and Type 2 diabetes formerly known as Non Insulin Dependent Diabetes Mellitus (NIDDM), representing the major part (85-90%). However, with the growing epidemic of obesity in all age categories, it is expected that in ten years time, there will be more children with type 2 than with type 1 [7].

Table 1: Estimated numbers of diabetics (in Million)

Country	2003	2025
India	35.5	73.5
China	23.8	46.1
United States	16	23.1
Russia	9.7	10.7
Japan	6.7	7.1
Germany	6.3	7.1
Pakistan	6.2	11.6
Brazil	5.7	10.7
Mexico	4.4	9
Egypt	3.9	7.8

Indeed, Obesity is another burden challenging the health authorities in almost all countries (high-income and low income alike), although with some variations within and between countries. In the United States, obesity prevalence has increased from 30% in the sixties to more than 60% as indicated by a recent study on obesity and the risk of heart failure which considered hypertension, diabetes and myocardial infarction, stressing that obesity promotes all three, and these promote heart failure [8]. In France, the proportion of obese children has grown from 12% in 1990 to 16% in 2000, which lead the health authorities to launch the Programme National Nutrition Santé in 2001 [9]. However, a special attention must be given to the contrasting effect in developing countries where obesity often coexists in the same population with chronic malnutrition and the burden of deaths and disability caused by non-communicable diseases outweighs that imposed by long-standing communicable diseases [1,10]. This global diagnosis being given, it is essential to stress that much of the cost of diabetes treatment is attributable to long term complications, such as blindness, kidney failure, heart disease, amputations and their economic and social consequences (care, hospitalization, absenteeism,...). Indeed, diabetes is:

- the leading cause of end-stage kidney failure necessitating dialysis or transplantation,
- the leading cause of blindness in people of working age,
- the leading cause of amputation,
- the first cause -with other risk factors- of mortality and morbidity by cardiovascular diseases.

The burden of diabetes and its complications

The exact costs of diabetes are not easy to pin down but estimations can be obtained according to three levels:

1. Cost directly related to the diagnosis and management of diabetes without complications. This includes the in-patient and out-patient care, means of treatment by insulin or tablets and the equipment of self control (blood and urine testing).

2. Costs generated by complications of diabetes. These are difficult to quantify because diabetes is linked to micro and macro vascular diseases such as heart disease, kidney failure, eye disease and amputation. Moreover, diabetes may add a cost of care by complicating other unrelated medical situations like infections, accidents and surgery.

3. Indirect costs correlated to the quality of life and the economic productivity which can be somehow estimated by the degree of disability.

In order to facilitate meaningful comparisons across world regions, costs are often expressed in international dollars (an international dollar has the same purchasing power as one US dollar has in the USA) and cost-effectiveness is measured in terms of years lived with disability (YLD) or disability adjusted life years (DALY) [11,12]. Studies in different countries have shown that diabetes is a costly disease accounting for between 2.5 and 15% of the total healthcare expenditure. For the age category 20–79, the world annual direct cost is estimated to be over 153 billion and expected to double in 2025 [2,13-16]. According to the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) and the American Diabetes Association, diabetes was the sixth leading cause of death in 1999 with a direct cost of \$44 billion and an indirect cost of \$54 billion annually. In 2002, the direct and indirect cost totaled \$132 billion [14]. In France, an estimation of \$5.7 billion was given for the direct cost of diabetes [5], whereas, an equivalent cost of £5.2 billion, representing approximately 9% of the annual national health service (NHS) budget, was given for UK in 2000

[15]. The burden affects also developing countries as stressed by the different authors who attended the seventh congress of the Pan-African diabetes study group in 2001 [16] and the Metabolic Syndrome type II Diabetes and Artherosclerosis Congress in 2004 [17]. In these, countries, until recently, it was widely believed that economic development was a necessary prerequisite for improving a population health status and the health was often classified as a non productive sector. Now, politicians and health policy makers are timidly recognizing that investing in people's health is a necessary condition for economic development but energetic decisions are needed for the adoption of urgent and consequent strategies. The need for such strategies is enhanced by the fact that risk factors like cholesterol, tobacco, blood pressure, and obesity are no more a specificity of industrialized countries, they are becoming more prevalent in developing nations, where they double the burden of infectious diseases that have always afflicted poorer countries [10].

The literature dealing with modeling for diabetes is mainly concerned with glucose and insulin dynamics [6,18-20], the epidemiology of the disease [21-23] and economic cost and risk models [24-29]. In previous papers, the authors considered continuous and matrix models for age structured populations of diabetics [30,31] and Dynamics of a disabled population in Morocco [32]. In the present paper, while stressing the growing burden of disease caused by diabetes and its complications, a model is proposed to monitor the size of the diabetic population and to deal with the evolution from the stage of diabetes without complications to the stage of diabetes with complications. Parameters can be handled to illustrate the effect of an increasing or decreasing incidence of diabetes and its complications. Consequently, different strategies can be adopted. The main purpose is to show that investment in primary health care is a necessary and cost-effective strategy that allow to control the incidences of diabetes and its complications and hence, to convince policy makers that bold decisions must be taken for a sustainable development which ensures better quality of life and well-being for the present and future generations of humans.




Figure 1
The mathematical model

Methods

The mathematical model

Suppose that $C = C(t)$ and $D = D(t)$ represent the numbers of diabetics with and without complications, respectively, and let $N = N(t) = C(t) + D(t)$ denote the size of the population of diabetics at time t (see Nomenclature). Then, as was noted earlier, $N(t) \sim 3\%$ of the world population. Let $I = I(t)$ denote the incidence of diabetes mellitus. The model parameters to be incorporated are μ (the natural mortality rate), λ (the probability of a diabetic person developing a complication), γ (the rate at which complications are cured), ν (the rate at which diabetic patients with complications become severely disabled) and δ (the mortality rate due to complications).

A schematic representation of the model is shown in Figure 1.

The diagram shows that $I = I(t)$ cases are diagnosed in a time interval of length t and are assumed to have no complications upon diagnosis. In that same time interval, the number of sufferers without complications, $D = D(t)$, is seen to decrease by the amounts μD (natural mortality) and λD (sufferers who develop complications), and to increase by the amount γC (sufferers whose complications are cured). During this time interval, the number of diabetics with complications is increased by the aforementioned amount γC and by the amount μC (natural mortality), νC (patients who become severely disabled and whose disabilities cannot be cured) and δC (those who die from their complications).

These rates of change are formalized by the ordinary differential equations (ODEs)

$$\begin{aligned} D'(t) &= \frac{dD(t)}{dt} = I - (\lambda + \mu)D(t) + \gamma C(t), \\ C'(t) &= \frac{dC(t)}{dt} = I + \lambda D(t) \\ &\quad - (\gamma + \mu + \nu + \delta)C(t), \end{aligned}$$

which, since $N(t) = D(t) + C(t)$, give rise to the initial-value problem (IVP)

$$C'(t) = -(\lambda + \theta)C(t) + \lambda N(t), \quad t > 0; \quad C(0) = C_0 \quad (1)$$

$$N'(t) = I(t) - (\nu + \delta)C(t) - \mu N(t), \quad t > 0; \quad N(0) = N_0 \quad (2)$$

where $\theta = \gamma + \mu + \nu + \delta$, $N'(t) = \frac{dN(t)}{dt}$ and C_0, N_0 are the initial values of $C(t)$ and $N(t)$, respectively.

In the case when the probability of a diabetic person developing a complication, λ , is constant, the model

equations (1), (2) are linear in $C(t)$ and $N(t)$: this linear model will be discussed in the following paragraph. The non-linear model corresponding to a variable λ will be considered by the authors in another paper more devoted to numerical analysis.

The linear case

The critical point and its stability property

The probability of developing a complication, λ , will be estimated to have the constant value

$$\lambda = \frac{C_0}{N_0}. \quad (3)$$

The initial-value problem (1), (2) may consequently be written in matrix-vector form as

$$x'(t) = Ax(t) + b(t), \quad t > 0; x(0) = X_0 \quad (4)$$

in which

$$x(t) = \begin{pmatrix} C(t) \\ N(t) \end{pmatrix}, A = \begin{pmatrix} -\lambda - \theta & \lambda \\ -\nu - \delta & -\mu \end{pmatrix}, \\ b(t) = \begin{pmatrix} 0 \\ I(t) \end{pmatrix}, X_0 = \begin{pmatrix} C_0 \\ N_0 \end{pmatrix}. \quad (5)$$

Suppose that I is the steady-state value of the incidence, then the model reaches its critical point when dC/dt and dN/dt given in (1) and (2) vanish simultaneously, that is when

$$\lambda N - (\lambda + \theta)C = 0, \quad (6)$$

$$I - \mu N - (\nu + \delta)C = 0. \quad (7)$$

Solving (6) and (7) gives

$$C^* = \frac{\lambda I}{\mu\lambda + \mu\theta + \lambda\delta + \lambda\nu}$$

and

$$N^* = \frac{(\lambda + \theta)I}{\mu\lambda + \mu\theta + \lambda\delta + \lambda\nu} \quad (8)$$

The eigenvalues of the matrix A , χ_1 , χ_2 , are the roots of the quadratic equation (the characteristic equation)

$$\chi^2 + (\lambda + \theta + \mu)\chi + \mu(\lambda + \theta) + \lambda(\nu + \delta) = 0. \quad (9)$$

The discriminant, Δ , of this equation is given by

$$\Delta = (\lambda + \theta + \mu)^2 - 4 [\mu(\lambda + \theta) + \lambda(\nu + \delta)]$$

and, recalling that $\theta = \nu + \mu + \delta + \gamma$ it follows that

$$\Delta < \lambda + \mu + \delta + \gamma + 2\nu.$$

Solving (9) gives

$$\chi_1 = \frac{-(\lambda + \mu + \delta + \gamma + 2\nu) + \Delta^{1/2}}{2} \text{ and} \\ \chi_2 = \frac{-(\lambda + \mu + \delta + \gamma + 2\nu) - \Delta^{1/2}}{2} \quad (10)$$

and it is then easy to check that, when the parameters of the model are such that

(a) $\Delta > 0$, χ_1 , χ_2 are both real and negative;

(b) $\Delta = 0$, $\chi_1 = \chi_2$ are real and negative;

(c) $\Delta < 0$, χ_1 and χ_2 are complex conjugate with negative real parts.

it may be concluded, therefore, that the critical point (C^*, N^*) of (1), (2), given by (8), is stable.

Numerical solution and stability

It may be shown that the solution $x(t)$ of the IVP (4) satisfies the recurrence relation

$$x(t+l) = \exp(lA)x(t) \\ + \int_t^{t+l} \exp[(t+l-s)A]b(s)ds; t = 0, l, 2l, \dots \quad (11)$$

where $l > 0$ is an increment in t (the time step). This recurrence relation may be used to generate $x(t_{n+1})$ in terms of $x(t_n)$, thus monitoring $C(t)$ and $N(t)$ at the discrete points $t = t_n = nl (n = 0, 1, 2, \dots)$.

One very simple way of estimating $x(t+l)$ is to approximate to second order the integral in (11) by the trapezoidal rule, viz.

$$\int_t^{t+l} \exp[(t+l-s)A]b(s)ds \approx \frac{1}{2}l[b(t+l) + \exp(lA)b(t)] \quad (12)$$

and then to replace, also to second order, $\exp(lA)$ in (11) and (12) by its (1,1) Padé approximant

$$\exp(lA) = (E - 1/2lA)^{-1} (E + 1/2lA) \quad (13)$$

where E is the identity matrix of order two.

Denoting by X_n the numerical approximation to $x(t_n)$ calculated using (11), (13), it may be shown, by substituting (12) with (13) in (11) and then by pre-multiplying by $(E - 1/2lA)$, that

$$(E - 1/2lA)X_{n+1} = (E + 1/2lA)X_n \quad (14)$$

+

$$1/2l[(E - 1/2lA)b_{n+1} + (E + 1/2lA)b_n]; n = 0, 1, 2, \dots$$

where $X_n = (C_n, N_n)^T$, T denoting transpose, and $b_n = (0, I_n)^T$ with $I_n = I(t_n)$. It may then be shown that C_{n+1} and N_{n+1} ($n = 0, 1, 2, \dots$) may be determined by solving the algebraic equations given by

$$\begin{aligned} (\text{Method 1}) \quad & (1 + 1/2l(\lambda + \theta))C_{n+1} - 1/2l\lambda N_{n+1} = \\ & [1 - 1/2l(\lambda + \theta)]C_n + 1/2l\lambda N_n - 1/4l^2\lambda(I_{n+1} - I_n) \end{aligned} \quad (15)$$

and

$$\begin{aligned} & 1/2l(\nu + \delta)C_{n+1} + (1 + 1/2l\mu)N_{n+1} = \\ & -1/2l(\nu + \delta)C_n + (1 - 1/2l\mu)N_n \\ & + 1/2l(1 + l\mu)I_{n+1} + 1/2l(1 - l\mu)I_n \end{aligned} \quad (16)$$

assuming convergence, $C_{n+1} = C_n = C$, $N_{n+1} = N_n = N$ and $I_{n+1} = I_n = I$, say, then equations (15) and (16) become

$$(\lambda + \theta)C - \lambda N = 0, \quad (17)$$

$$(\nu + \delta)C + \mu N = I, \quad (18)$$

respectively. Obviously (17) and (18) are the same as (6) and (7) and so the fixed point (C^*, N^*) of the numerical solution sequence (C_n, N_n) , $n = 0, 1, 2, \dots$ is the same as the critical point (C^*, N^*) of the linear initial value-problem.

For comparison purpose, the IVP (1), (2) was also solved using the well-known Euler method (a first-order method) given by

$$(\text{Method 2}) \quad C_{n+1} = [1 - l(\lambda + \theta)]C_n + l\lambda N_n \quad (19)$$

$$N_{n+1} = -l(\nu + \delta)C_n + (1 - l\mu)N_n + lI \quad (20)$$

The method1 is unconditionally stable whereas the Euler method is conditionally stable provided ([33])

Table 2: Parameter vlaues used in numerical experiments

Parameter	Value yr ⁻¹
ν	0.05
δ	0.05
μ	0.02
γ	0.08 or 0

$$l < \frac{4}{(\lambda + \theta + \mu) + \sqrt{(\lambda + \theta + \mu)^2 - 4\lambda(\nu + \delta)}} \quad (21)$$

Numerical experiments

Taking $I(t) = I$ to be constant equations (15) and (16) simplify to

$$\begin{aligned} & (1 + 1/2l(\lambda + \theta))C_{n+1} - 1/2l\lambda N_{n+1} = \\ & [1 - 1/2l(\lambda + \theta)]C_n + 1/2l\lambda N_n \end{aligned} \quad (22)$$

$$\begin{aligned} & 1/2l(\nu + \delta)C_{n+1} + (1 + 1/2l\mu)N_{n+1} = \\ & -1/2l(\nu + \delta)C_n + (1 - 1/2l\mu)N_n + lI, \end{aligned} \quad (23)$$

respectively, for $n = 0, 1, 2, \dots$. In the numerical experiments, I was given the value 6.10^6yr^{-1} and the parameters ν, δ, μ, γ were given the value shown in Table 2. the critical values of C and N were then calculated from (8) and were found to be

$$C^* = 47000000 \text{ and } N^* = 61100000. \quad (24)$$

Using Matlab, four numerical experiments were carried out taking as initial conditions

$$C_0 = C^* \pm 500 \text{ and } N_0 = N^* \pm 500. \quad (25)$$

A time step of $l = 0.01 \text{yr}^{-1}$ was used and the solution to the IVP (1), (2) was computed by solving (22), (23) for $n = 0, 1, 2, \dots$. Using all combinations of initial conditions, the computed solution converged to the values of C^* and N^* given in (24). By way of example, the fixed points, C^* and N^* , to which the numerical solution converged are shown in Table 3.

The initial conditions in (25) are close to the steady-state solutions C^* and N^* . Other initial conditions, further from C^* and N^* , will converge to the same values of C^* and N^* for the same value of l , though these values will be reached at different times.

Retaining the parameters values shown in Table 2 the effect of the choice of time step was monitored in a series of 11 further experiments. The fixed-point values, C^* and N^* to which convergence occurred are shown in Table 3, where it may be seen that, for the larger values of l ($l \geq 0.5 \text{yr}$), there is very close agreement with the critical-point values given in (24).

For $l \leq 2 \text{yr}$ (approximately), the two methods give similar results but for $l > 2.5 \text{yr}$ (approximately (21)) the Euler method diverged. The values of C^* and N^* using Euler method are given in Table 3.

Table 3: Fixed point values ($\times 10^7$) for the linear model using different values of I , $I = 6 \times 10^7$, $\lambda = 0.66$

	N^+	N^+	C^+	C^+
I yr	Euler	Method I	Euler	Method I
0.01	6.08	6.08	4.75	4.75
0.02	6.11	6.11	4.77	4.77
0.05	6.11	6.11	4.7	4.7
0.1	6.11	6.11	4.7	4.7
0.2	6.11	6.11	4.7	4.7
0.5	6.11	6.11	4.7	4.7
1	6.11	6.11	4.7	4.7
2	6.11	6.11	4.7	4.7
2.5	div	6.11	div	4.7
3	div	6.11	div	4.7
3.5	div	6.11	div	4.7
4	div	6.11	div	4.7

div = divergence of numerical methods.

It may be concluded from these results that the Euler method may be used with confidence if the diabetic population is to be monitored at time intervals up to approximately two years using the linear model (1), (2). However, to monitor the population less frequently the numerical method (Method 1) should be used.

Results and discussion

Nine scenarios were considered (Low-Low, Low-Medium, Low-High, Medium-Low, Medium-Medium, Medium-High, High-Low, High-Medium, and High-High) by combining the levels of incidence of diabetes and its complications. For instance, High-High refers to a high incidence of diabetes and high incidence of complications. These combinations are given by different values of the parameters I for incidence of diabetes and A for incidence of complications. The model shows clearly the differences in the global number of diabetics (N) and the number of diabetics with complications (C) as illustrated by Tables 4. The number of diabetics resulting from a strategy with high incidence may be reduced by half if a strategy with medium incidence is applied during a dozen of years. A further reduction by three can be obtained by a strategy with low incidence. But, more importantly, the rate of complications reaches 78% in a high strategy of complications, it can be reduced to 63% (respectively 53%) with a medium (respectively a low) strategy of complications. Now, are we really able to act on these incidences and how? Precise answers have been given at different levels.

For the incidence of diabetes, worldwide, it is now commonly admitted that efforts must be conjugated to reverse

or at least to attenuate its growing trend, otherwise, health authorities will be unable to provide care and treatments for millions of people who will be affected by diabetes in the future [1,2,7,16,34]. Propositions are mainly directed towards risk factors like obesity, tobacco inactivity, alcohol, blood pressure, cholesterol, inheritance and diet habits in general [4,6,35]. Many authors have dealt with complications [1,2,36,37]. The strategy can be summarized by the recommendations of The Saint Vincent Declaration [38] which fixed in 1989 the following objectives:

- Reduce new blindness due to diabetes by one third or more
- Reduce numbers of people entering end-stage diabetic renal failure by at least one third
- Reduce by one half the rate of limb amputations for diabetic gangrene
- Cut morbidity and mortality from coronary disease in the diabetic by vigorous programmes of risk factor reduction
- Achieve pregnancy outcome in the diabetic woman that approximates that of the non-diabetic woman.

However, although most of developed countries have reacted by pragmatic measures, the trend remain globally passive mainly because developing countries have been, so far, satisfied with adopting national conventions and adhering to international recommendations instead of

Table 4: Output of the nine scenarios according to each level of incidence I and complications λ ($\times 10^7$)

$I \lambda$	L	M	H
L	$C = 0.72$ $N = 1.36$	$C = 2.18$ $N = 4.09$	$C = 4.36$ $N = 8.18$
M	$C = 0.75$ $N = 1.20$	$C = 0.22$ $N = 3.6$	$C = 4.55$ $N = 7.21$
H	$C = 0.79$ $N = 1.0$	$C = 2.38$ $N = 3.05$	$C = 4.77$ $N = 6.11$

working in the field. As stressed earlier, this behaviour can be partly explained by lack of means and poor budget affected to health care but, in general, bad management and absence of goodwill assume a large part of responsibility. The illustration yielded by our mathematical model confirms the diagnosis and the recommendations given by specialists and experts in the field of diabetes and health management in general. Moreover, it gives to health decision makers guide lines of comparison between the social and economic costs of uncontrolled diabetes, and the benefit gained by a productive investment in primary healthcare.

Conclusion

In this paper, a mathematical model was proposed to deal with the dynamics of a population of diabetes. The model was formalized by a system of ordinary differential equations, then numerical approximations were used to obtain numerical results. Although linear and non-linear cases were considered, for sake of clarity and simplicity, only numerical results of the linear model were given.

The model showed clearly the results given according to different scenarios. The main purpose was to stress the importance to control the incidence of diabetes and its complications and hence to convince decision makers that investment in healthcare is a cost-effective strategy.

Authors contributions

AB participated to the proposition and discussion of the model.

EHT elaborated numerical analysis and English writing.

KA elaborated numerical experiments.

AC elaborated numerical procedures and T_EX writing.

Appendix

t : time,

l : increment in t (the time step),

$C(t)$: number of diabetics with complications,

$D(t)$: number of diabetics without complications,

$N(t)$: number of diabetics ($N = C + D$),

$I(t)$: incidence of diabetes mellitus,

J : jacobien,

μ : natural mortality rate,

λ : probability of developing a complication,

γ : rate at which complications are cured,

ν : rate at which patients with complications become severely disabled,

δ : mortality rate due to complications,

$\theta = \mu + \delta + \gamma + \nu$,

χ_1, χ_2 : eigenvalues,

C_0, N_0 : initial values of C and N ,

C^*, N^* : critical-point values of C and N ,

C^+, N^+ : fixed-point values of C and N ,

$x: x = [C, N]^T$, T denoting transpose,

$X_0: X_0 = [C_0, N_0]^T$,

A : constant square matrix of order two (linear model),

$b(t): b(t) = [0, I(t)]^T$,

C_n, N_n : approximations to $C(nl), N(nl)$,

$X_n: X_n = [C_n, N_n]^T$,

$I_n: I_n = I(nl)$.

Acknowledgements

One of the authors (A.B) is grateful to the British Council (Morocco) for financial support during the period of research. This paper is dedicated to Wiam Boutayeb and David M. Barlett.

References

1. The world health report: **Today's challenges**. Geneva, World Health Organization [http://www.who.int/whr/2003/en].
2. International Diabetes Federation: **IDF report**. 2003 [http://www.idf.org/home/index.cfm].
3. The Expert Committee on the diagnosis and classification of diabetes mellitus: **Report**. *Diabetes care* 1997, **20**:1183-96.
4. Diet, Nutrition and the prevention of Chronic Diseases: **Report of joint WHO/FAO Expert Consultation**. Geneva, World Health Organization, WHO Technical report Series 916 2003.
5. Mayo M: **Le diabète: Une épidémie silencieuse**. *Science et vie* 2004, **1037**:100-113.
6. Derouich M, Boutayeb A: **The effect of physical exercise on the dynamics of glucose and insulin**. *Journal of Biomechanics* 2002, **35**:911-917.
7. Borys JM: **Diabète et prédiabète: repenser la prévention**. [http://www.diabsurf.com].
8. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS: **Obesity and the risk of heart failure**. *N Engl J Med* 2002, **347**:305-313.
9. Beme D: **Intervenir en amont de l'obésité**. [http://www.doctis.simo.fr/html/sante/obesite].
10. The world health report 2002: **Reducing Risk: Promoting Health Life**. Geneva, World Health Organization 2002 [http://www.who.int/whr/2002/en].
11. Hutubessy R, Chisholm D, Edjer TT: **For WHO-CHOICE Generalized cost-effectiveness analysis for national-level priority setting in health sector**. *Cost Effectiveness and Resources Allocation* 2003, **1**(1):8.
12. Mathers CD, Bernard C, Iburg KM, Inoue M, Fat DM, Shibuya K, Stein C, Tomijima N, Xu H: **Global Burden of Disease in 2002 data sources, methods and results**. *Paper 54 WHO*.
13. Currie JC, Krans D, Morgan CL, Gill L, Stott NC, Peters JR: **NHS acute sector expenditure for diabetes, and excess in-patient cost of care**. *Diabetic Medicine* 1997, **14**:686-692.
14. OHSU Health: **General diabetes statistics**. [http://www.ohsuhealth.com/diabetes/stats.asp].
15. Fact sheet N03: **Diabetes: cost and complications**. [http://www.diabete.org.uk/infocentre/].
16. Belkhadir J: **Le diabète en milieu marocain en 2001** [http://www.marocsante.com/html/diabetes].
17. MSDAC 2004: **Metabolic syndrome type II diabetes, and atherosclerosis congress**. [http://www.msdac.com].
18. Lehmann ED, Deutsch T: **Application of computers in diabetes care a review**. *Med Inform* 1995, **20**:281-302.
19. Bellazzi R, Nucci G, Cobelli C: **The subcutaneous route to insulin-dependent diabetes theory**. *IEEE Eng Med Biol Mag* 2001, **20**:56-64.
20. Parker RS, Doyle FJ, Peppas NA: **The intravenous route to blood glucose control**. *IEEE Eng Med Biol Mag* 2001, **24**:65-73.
21. Staines A, Bodansky HJ, Lilley HEB, Stephenson C, McNally RJQ, Cartwright RA: **The epidemiology of diabetes mellitus in the United Kingdom**. *Diabetologia* 1993, **36**:1282-1287.
22. Patterson C, Thorogood M, Smith PG, Heasman MA, Clarke MA, Mam JI: **Epidemiology of type I diabetes in Scotland: evidence of an increasing incidence**. *Diabetologia* 1983, **24**:238-243.
23. Boutayeb A, Kerfati A: **Mathematical models in diabetology Modelling**. *Measurement and Control, C, AMSE* 1994, **44**:53-63.
24. Bagust A, Hopkinson PK, Maslove L, Currie CJ: **The projected health care burden of type diabetes in the UK from 2000 to 2006**. *Diabet Med* 2002, **19**:1-5.
25. Richard JS, Khothari V, Amanda IA, Stratton IM, Holman RR: **The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)**. *Clinical Science* 2001, **101**:671-679.
26. Bagust A, Hopkinson PK, Maier W, Currie CJ: **An economic model of the long-term health care burden of type II diabetes**. *Diabetologia* 2001, **12**:2140-55.
27. O'Brien JA, Patrick AR, Caro J: **Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000**. *Clin Ther* 2003, **3**:1017-38.
28. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA: **The economic costs of non-insulin-dependent diabetes mellitus**. *JAMA* 1989, **262**:2708-13.
29. Gozzoli V, Palmer AJ, Brandt A, Spinaz GA: **Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting**. *Swiss Med Wkly* 2001, **131**:303-10.
30. Boutayeb A, Derouich M: **Age structured models for diabetes in East Morocco**. *Mathematics and Computers in Simulation* 2002, **58**:215-229.
31. Boutayeb A, Twizell EH: **An age structure model for complications of diabetes mellitus in Morocco**. *Simulation Modelling Practice and Theory* 2004, **12**:77-87.
32. Boutayeb A, Chetouani A: **Dynamics of a disabled population in Morocco**. *BioMedical Engineering Online* 2003, **2**:2.
33. Achouyab K: **Modélisation mathématique en diabétologie: Conception et étude numérique**. Ph D thesis Oujda University, Morocco; 1996.
34. Le Jeune S: **Le diabète, une catastrophe pire que le SIDA**. [http://www.diabsurf.com].
35. **Recommandations de l'Alfediam Diabète et Métabolisme**. Paris 1995, **21**:59-62.
36. **DCCT**. *New Engl J Med* 1996, **329**:977-986.
37. **UKPDS: Tight blood pressure and risk of macrovascular and microvascular complications in type 2 diabetes**. *Brit Med J* 1998, **317**:703-713.
38. Krans HMJ, Porta M, Keen H: **Diabetes Care and Research in Europe: The Saint Vincent Declaration Action Program**. WHO, regional office for Europe 1992.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

